Editing Primary biliary cholangitis (section)

===Other therapies===
* Fatigue is a nonspecific but often-reported symptom in PBC, and represents an unmet need since no therapies are licensed. A structured approach to management, quantifying fatigue and its impacts (through the use of disease-specific tools such as the PBC-40 quality-of-life measures), addressing contributing and exacerbating factors, and supporting patients to cope with its impact is effective. Drugs such as coenzyme Q and rituximab have been shown to be ineffective. A graded programme of exercise helps some individuals.{{citation needed|date=April 2021}}
* People with PBC may have poor lipid-dependent absorption of oil-soluble vitamins (A, D, E, and K).<ref name="BaconO'Grady2006">{{cite book | vauthors = Bacon BR, O'Grady JG | title = Comprehensive Clinical Hepatology|url=https://books.google.com/books?id=ec0G9HGiR8MC&pg=PA283 | access-date = 29 June 2010 | year = 2006 | publisher = Elsevier Health Sciences | isbn = 978-0-323-03675-7 | pages = 283– | name-list-style = vanc }}</ref> Appropriate supplementation is recommended when bilirubin is elevated.<ref name="pmid=19554543"/>
* People with PBC are at elevated risk of developing osteoporosis<ref>{{cite journal | vauthors = Collier JD, Ninkovic M, Compston JE | title = Guidelines on the management of osteoporosis associated with chronic liver disease | journal = Gut | volume = 50 | issue = Suppl 1 | pages = i1–i9 | date = February 2002 | pmid = 11788576 | pmc = 1867644 | doi = 10.1136/gut.50.suppl_1.i1 }}</ref> as compared to the general population and others with liver disease. Screening and treatment of this complication is an important part of the management of PBC.
* As in all liver diseases, consumption of [[alcohol (drug)|alcohol]] should be restricted or eliminated.
* In patients with advanced liver disease, the only curative therapy is [[Liver transplantation|liver transplant]]. Outcomes are favourable, with five-year patient survival rates better than for most other indications for LT (80–85%).<ref name="k&c-p155">{{cite book | vauthors = Clavien PA, Killenberg PG |title=Medical Care of the Liver Transplant Patient: Total Pre-, Intra- and Post-Operative Management |publisher=Wiley-Blackwell |year=2006 |page=155 |isbn=978-1-4051-3032-5 }}</ref><ref name="pmid21923804">{{cite journal | vauthors = Kaneko J, Sugawara Y, Tamura S, Aoki T, Hasegawa K, Yamashiki N, Kokudo N | title = Long-term outcome of living donor liver transplantation for primary biliary cirrhosis | journal = Transplant International | volume = 25 | issue = 1 | pages = 7–12 | date = January 2012 | pmid = 21923804 | doi = 10.1111/j.1432-2277.2011.01336.x | s2cid = 19872625 | doi-access = free }}</ref>